Loading
A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) is a phase 3 interventional study registered as NCT06305754 by Merck Sharp & Dohme LLC, with 550 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-08-17. Interventions recorded: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Platinum agents.
Shares Sacituzumab tirumotecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin.